---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-000073"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T17:59:13.865018+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics appoints Eduardo Rene Salas to Board of Directors

## Summary
- Appointed Eduardo Rene Salas as Class I director, term expiring at 2026 annual meeting.
- Salas is former EY audit partner (2002-2019) and former CFO of Wellstat Therapeutics (2020-2022).
- He currently serves on audit committee of Intra-Cellular Therapies (since 2022).
- He will receive initial grant of options to purchase 20,011 shares of common stock.
- No material transactions or arrangements in connection with appointment.

## SEC filing metadata
- accession: 0001140361-25-000073
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036125000073/0001140361-25-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036125000073/ef20040947_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-000073
- JSON: https://secwatch.observer/filing/0001140361-25-000073.json
- Plain text: https://secwatch.observer/filing/0001140361-25-000073.txt

## Key facts
- Executive change
  Eduardo Rene Salas was appointed as Class I Director at ADMA BIOLOGICS, INC..
  - Action: appointed
  - Role: Class I Director
  source text: On December 30, 2024, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Eduardo Rene Salas to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036125000073/0001140361-25-000073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.